Bausch & Lomb may be worth about $28 a share in takeover - analyst
Financial analyst predicts Bausch & Lomb (BLCO) could be worth $28/share in a potential takeover, with private equity ...
Private Equity Interest Signals Upside for Bausch + Lomb: A Buy Rating Justified
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
Longview News-Journal20d
Intraocular Lens (IOLs) Market to Expand by USD 1.17 Billion (2024-2028), Driven by Rising Ophthalmic Disease Rates and AI Trends - Technavio Report
Alcon Inc., Aurolab, Bausch Lomb Corp., BVI Holdings Ltd., Carl Zeiss AG, EyeKon Medical Inc., HOYA CORP., HumanOptics Holding AG, Johnson and Johnson Services Inc ...
Future Market Insights3d
Ophthalmic Eye Drop Market to Reach USD 25,876.4 Million by 2034, Expanding at a CAGR of 4.7%
The global ophthalmic eye drop market is poised for steady growth over the next decade. The market, which was valued at USD ...
ophthalmologytimes8d
Treating meibomian gland dysfunction and glaucoma
Common glaucoma treatments may worsen ocular surface disease and meibomian gland dysfunction, leading to discomfort, redness, ...
Stockhouse19d
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
Mr. Hassan’s past directorships include Time Warner (2001-2018), Amgen (2015-2021) and as Chairman at Bausch & Lomb (2010-2013 ... for the localized treatment of all ophthalmic ...